SI9300468A - Injectable composition for the sustained release of biologically active compounds - Google Patents
Injectable composition for the sustained release of biologically active compounds Download PDFInfo
- Publication number
- SI9300468A SI9300468A SI9300468A SI9300468A SI9300468A SI 9300468 A SI9300468 A SI 9300468A SI 9300468 A SI9300468 A SI 9300468A SI 9300468 A SI9300468 A SI 9300468A SI 9300468 A SI9300468 A SI 9300468A
- Authority
- SI
- Slovenia
- Prior art keywords
- solvent
- lecithin
- composition according
- additives
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 23
- 238000013268 sustained release Methods 0.000 title abstract description 7
- 239000012730 sustained-release form Substances 0.000 title abstract description 7
- 239000007972 injectable composition Substances 0.000 title description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 58
- 239000000787 lecithin Substances 0.000 claims abstract description 58
- 235000010445 lecithin Nutrition 0.000 claims abstract description 58
- 229940067606 lecithin Drugs 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims description 76
- 239000002904 solvent Substances 0.000 claims description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 26
- 102000014150 Interferons Human genes 0.000 claims description 23
- 108010050904 Interferons Proteins 0.000 claims description 23
- 229940079322 interferon Drugs 0.000 claims description 23
- 239000000654 additive Substances 0.000 claims description 21
- 235000012000 cholesterol Nutrition 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000002357 osmotic agent Substances 0.000 claims description 10
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims description 9
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 9
- 101710142969 Somatoliberin Proteins 0.000 claims description 9
- 235000021355 Stearic acid Nutrition 0.000 claims description 8
- 125000005456 glyceride group Chemical group 0.000 claims description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 8
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 8
- 239000008117 stearic acid Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- -1 polyoxyethylene Polymers 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 10
- 241000124008 Mammalia Species 0.000 abstract description 3
- 230000002459 sustained effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 28
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 14
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 102000006992 Interferon-alpha Human genes 0.000 description 9
- 108010047761 Interferon-alpha Proteins 0.000 description 9
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 239000005695 Ammonium acetate Substances 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 235000019257 ammonium acetate Nutrition 0.000 description 7
- 229940043376 ammonium acetate Drugs 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 7
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 7
- 229960002216 methylparaben Drugs 0.000 description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 7
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 7
- 229960003415 propylparaben Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 description 2
- 235000003276 Apios tuberosa Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- XUGISPSHIFXEHZ-UHFFFAOYSA-N 3beta-acetoxy-cholest-5-ene Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 XUGISPSHIFXEHZ-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 101000577129 Homo sapiens Monocarboxylate transporter 5 Proteins 0.000 description 1
- 101000577131 Homo sapiens Monocarboxylate transporter 6 Proteins 0.000 description 1
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100025273 Monocarboxylate transporter 5 Human genes 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- XUGISPSHIFXEHZ-VEVYEIKRSA-N cholesteryl acetate Chemical compound C1C=C2C[C@@H](OC(C)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 XUGISPSHIFXEHZ-VEVYEIKRSA-N 0.000 description 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96075292A | 1992-10-14 | 1992-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI9300468A true SI9300468A (en) | 1994-06-30 |
Family
ID=25503572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9300468A SI9300468A (en) | 1992-10-14 | 1993-09-08 | Injectable composition for the sustained release of biologically active compounds |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5863549A (is) |
| EP (1) | EP0620740B1 (is) |
| JP (1) | JP2613750B2 (is) |
| CN (1) | CN1090509A (is) |
| AT (1) | ATE180976T1 (is) |
| AU (1) | AU672441B2 (is) |
| CA (1) | CA2125784A1 (is) |
| DE (1) | DE69325256T2 (is) |
| ES (1) | ES2133413T3 (is) |
| IL (1) | IL107207A0 (is) |
| IS (1) | IS4083A (is) |
| LV (1) | LV10180A (is) |
| MX (1) | MX9306239A (is) |
| NZ (1) | NZ256413A (is) |
| RU (1) | RU94033520A (is) |
| SI (1) | SI9300468A (is) |
| UY (1) | UY23665A1 (is) |
| WO (1) | WO1994008623A1 (is) |
| ZA (1) | ZA937459B (is) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USD358485S (en) | 1992-10-05 | 1995-05-23 | Colgate-Palmolive Company | Toothbrush handle |
| US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US6264902B1 (en) | 1996-06-28 | 2001-07-24 | Johnson & Johnson Medical, Inc. | Instrument sterilization container having an improved latching mechanism |
| US6379631B1 (en) | 1996-06-28 | 2002-04-30 | Johnson & Johnson Medical, Inc. | Instrument sterilization container formed of a liquid crystal polymer |
| EP1093348A4 (en) * | 1998-06-29 | 2003-07-16 | Pharmaceuticals Applic Asociat | TRANSDERMAL ANALGESIC COMPOSITIONS AND METHODS OF ADMINISTRATION |
| US8052982B2 (en) | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
| AU755443C (en) * | 1998-07-20 | 2006-08-17 | Virbac (Australia) Pty Limited | Bioimplant formulation |
| ES2389627T3 (es) | 1998-07-20 | 2012-10-29 | Virbac (Australia) Pty Ltd | Formulación para bioimplantes |
| EP1064934A1 (en) * | 1999-06-30 | 2001-01-03 | Applied Research Systems ARS Holding N.V. | GRF-containing lyophilized pharmaceutical composition |
| US6191121B1 (en) * | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
| US6979459B1 (en) | 2000-04-06 | 2005-12-27 | Perricone Nicholas V | Treatment of skin damage using polyenylphosphatidycholine |
| US6932963B2 (en) | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
| US20020106406A1 (en) * | 2000-12-08 | 2002-08-08 | Mchugh Anthony J. | Crystallizable/non-crystallizable polymer composites |
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| BR0308137A (pt) * | 2002-03-04 | 2005-01-04 | Sod Conseils Rech Applic | Formulações de droga de liberação constante contendo um peptìdeo veìculo |
| US7691408B2 (en) | 2002-03-12 | 2010-04-06 | Ethypharm | Composition having gelling properties for the prolonged delivery of bioactive substances |
| KR100906547B1 (ko) | 2002-03-12 | 2009-07-07 | 에띠빠흠 | 생활성 물질의 지속적 전달을 위한 겔화 특성을 갖는 조성물 |
| US20040025791A1 (en) * | 2002-08-09 | 2004-02-12 | Applied Materials, Inc. | Etch chamber with dual frequency biasing sources and a single frequency plasma generating source |
| FR2868704B1 (fr) * | 2004-04-07 | 2007-09-14 | Ethypharm Sa | Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires |
| JP2008502690A (ja) * | 2004-06-15 | 2008-01-31 | アンドリュー シァン チェン， | リン脂質組成物ならびにその調製方法および使用方法 |
| US7858115B2 (en) * | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| WO2006116565A2 (en) * | 2005-04-25 | 2006-11-02 | Amgen Inc. | Biodegradable peptide sustained release compositions containing porogens |
| US7695633B2 (en) * | 2005-10-18 | 2010-04-13 | Applied Materials, Inc. | Independent control of ion density, ion energy distribution and ion dissociation in a plasma reactor |
| CU23432B6 (es) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
| PT1787658E (pt) | 2005-11-10 | 2012-06-22 | Chemi Spa | Formulações de libertação sustentada de análogos de somatostatina inibidores da hormona do crescimento |
| US8017159B2 (en) * | 2005-11-16 | 2011-09-13 | Idexx Laboratories, Inc. | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same |
| US20070245961A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source for controlling plasma ion dissociation |
| US20070245958A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source for controlling ion radial distribution |
| US7645357B2 (en) * | 2006-04-24 | 2010-01-12 | Applied Materials, Inc. | Plasma reactor apparatus with a VHF capacitively coupled plasma source of variable frequency |
| US20070245960A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion density |
| US7727413B2 (en) * | 2006-04-24 | 2010-06-01 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source to control plasma ion density |
| US7780864B2 (en) * | 2006-04-24 | 2010-08-24 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion radial distribution |
| US20070246443A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma process for controlling plasma ion dissociation |
| US20070246163A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with independent capacitive and inductive plasma sources |
| US20070246161A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with a toroidal plasma source and a VHF capacitively coupled plasma source with variable frequency |
| US20070246162A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with an inductive plasma source and a VHF capacitively coupled plasma source with variable frequency |
| US7403325B2 (en) * | 2006-05-19 | 2008-07-22 | Xerox Corporation | Electrophoretic display device |
| JP5731198B2 (ja) | 2007-09-27 | 2015-06-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用 |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| TWI539959B (zh) | 2008-02-11 | 2016-07-01 | 菲瑞茵國際中心股份有限公司 | 治療轉移階段攝護腺癌的方法 |
| WO2009114959A1 (zh) * | 2008-03-20 | 2009-09-24 | 中国人民解放军军事医学科学院毒物药物研究所 | 可注射用缓释药物制剂及其制备方法 |
| JP5715051B2 (ja) | 2008-06-05 | 2015-05-07 | イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物 |
| AU2010243273B2 (en) * | 2009-05-01 | 2016-06-16 | Ferring B.V. | Composition for the treatment of prostate cancer |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| WO2011075623A1 (en) | 2009-12-18 | 2011-06-23 | Latitude Pharmaceuticals, Inc. | One - phase gel compos ition compri s ing phos pholi pids |
| BR112013003934A2 (pt) | 2010-08-20 | 2016-06-07 | Reddys Lab Ltd Dr | depot de fosfolipídeos |
| WO2012054447A2 (en) | 2010-10-22 | 2012-04-26 | Dr. Reddy's Laboratories, Inc. | Use of storage stable viscous phospholipid depot to treat wounds |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| LT2632934T (lt) | 2010-10-27 | 2017-01-10 | Ferring B.V. | Degarelikso ir jo tarpinių darinių gamybos būdas |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| WO2012170796A1 (en) * | 2011-06-09 | 2012-12-13 | Amylin Pharmaceuticals, Inc. | Gel compositions |
| US10105435B2 (en) | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
| IN2014MN02213A (is) * | 2012-05-10 | 2015-07-10 | Painreform Ltd | |
| PL4512389T1 (pl) | 2012-06-01 | 2025-09-01 | Ferring B.V. | Produkt leczniczy degareliksu |
| KR102227966B1 (ko) * | 2019-06-26 | 2021-03-16 | 주식회사 엠이티라이프사이언스 | 비활성 폴리펩타이드 ｔｒｐ의 약제학적 제형 |
| CN119792245A (zh) * | 2025-01-08 | 2025-04-11 | 中国药科大学 | 一种可注射缓释制剂及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4377567A (en) * | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
| US4252793A (en) * | 1979-06-18 | 1981-02-24 | American Lecithin Company | Injectable lecithin preparation |
| US4297353A (en) * | 1980-08-04 | 1981-10-27 | Sandoz, Inc. | Non-irritating injectable dosage forms |
| US4578391A (en) * | 1982-01-20 | 1986-03-25 | Yamanouchi Pharmaceutical Co., Ltd. | Oily compositions of antitumor drugs |
| FR2562421B1 (fr) * | 1984-04-09 | 1989-02-17 | Sandoz Sa | Perfectionnements a la therapie par l'interleukine |
| US4761288A (en) * | 1984-09-24 | 1988-08-02 | Mezei Associates Limited | Multiphase liposomal drug delivery system |
| GB8603621D0 (en) * | 1986-02-14 | 1986-03-19 | Habib N | Modifying lipid structure of cell membranes |
| US5084269A (en) * | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
| NZ222907A (en) * | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| CH681427A5 (is) * | 1987-07-01 | 1993-03-31 | Zambon Spa | |
| JP2643217B2 (ja) * | 1988-01-22 | 1997-08-20 | エーザイ株式会社 | 脂溶性物質水性液 |
| US5124151A (en) * | 1990-08-07 | 1992-06-23 | Mediventures Inc. | Drug delivery by injection with thermo-irreversible gels |
| US5143731A (en) * | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| US5505877A (en) * | 1991-10-15 | 1996-04-09 | Krivohlavek; Dennis | Making multiple phase emulsion or gel |
| DE4201527A1 (de) * | 1992-01-21 | 1993-07-22 | Knoll Ag | Lecithinhaltige loesungen mit levemopamil |
| US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| US5660854A (en) * | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
-
1993
- 1993-09-08 SI SI9300468A patent/SI9300468A/sl unknown
- 1993-10-05 ES ES93921914T patent/ES2133413T3/es not_active Expired - Lifetime
- 1993-10-05 RU RU94033520/14A patent/RU94033520A/ru unknown
- 1993-10-05 AT AT93921914T patent/ATE180976T1/de not_active IP Right Cessation
- 1993-10-05 DE DE69325256T patent/DE69325256T2/de not_active Expired - Fee Related
- 1993-10-05 WO PCT/EP1993/002711 patent/WO1994008623A1/en not_active Ceased
- 1993-10-05 CA CA002125784A patent/CA2125784A1/en not_active Abandoned
- 1993-10-05 JP JP6509578A patent/JP2613750B2/ja not_active Expired - Fee Related
- 1993-10-05 EP EP93921914A patent/EP0620740B1/en not_active Expired - Lifetime
- 1993-10-05 AU AU51110/93A patent/AU672441B2/en not_active Ceased
- 1993-10-05 NZ NZ256413A patent/NZ256413A/en unknown
- 1993-10-06 IL IL107207A patent/IL107207A0/xx unknown
- 1993-10-07 ZA ZA937459A patent/ZA937459B/xx unknown
- 1993-10-07 MX MX9306239A patent/MX9306239A/es unknown
- 1993-10-13 IS IS4083A patent/IS4083A/is unknown
- 1993-10-13 LV LV931150A patent/LV10180A/xx unknown
- 1993-10-13 CN CN93119112A patent/CN1090509A/zh active Pending
- 1993-10-13 UY UY23665A patent/UY23665A1/es unknown
-
1996
- 1996-08-22 US US08/701,274 patent/US5863549A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2133413T3 (es) | 1999-09-16 |
| IL107207A0 (en) | 1994-01-25 |
| DE69325256D1 (de) | 1999-07-15 |
| ZA937459B (en) | 1994-04-14 |
| JP2613750B2 (ja) | 1997-05-28 |
| CA2125784A1 (en) | 1994-04-28 |
| LV10180A (lv) | 1994-10-20 |
| RU94033520A (ru) | 1996-11-10 |
| ATE180976T1 (de) | 1999-06-15 |
| DE69325256T2 (de) | 1999-12-16 |
| UY23665A1 (es) | 1994-04-06 |
| EP0620740B1 (en) | 1999-06-09 |
| MX9306239A (es) | 1994-06-30 |
| AU672441B2 (en) | 1996-10-03 |
| AU5111093A (en) | 1994-05-09 |
| CN1090509A (zh) | 1994-08-10 |
| NZ256413A (en) | 1996-07-26 |
| IS4083A (is) | 1994-04-15 |
| EP0620740A1 (en) | 1994-10-26 |
| US5863549A (en) | 1999-01-26 |
| JPH06511263A (ja) | 1994-12-15 |
| WO1994008623A1 (en) | 1994-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9300468A (en) | Injectable composition for the sustained release of biologically active compounds | |
| US12396944B2 (en) | Injectable buprenorphine formulation | |
| CN100479856C (zh) | 用于亲水性化合物非肠道给药的缓释药物组合物 | |
| JP5107725B2 (ja) | ＧｎＲＨ類似体製剤 | |
| CN101217940B (zh) | Glp-1类似物制剂 | |
| US6719992B2 (en) | Non-aqueous surfactant-containing formulations for extended release of somatotropin | |
| EP0220153B1 (en) | A nutritive emulsion having oxygen-transporting properties, and process for its preparation | |
| JP2008526933A (ja) | ソマトスタチン類似体製剤 | |
| US4775659A (en) | Injectable semi-solid formulations | |
| EP0351651B1 (en) | Insulin preparation | |
| EP0719561A1 (en) | Percutaneously absorbable preparation | |
| HUT75252A (en) | Oral pharmaceutical compositions | |
| KR20200135280A (ko) | 지속 방출 펩티드 제형 | |
| JP3848537B2 (ja) | ドラメクチン製剤 | |
| US9956164B2 (en) | Veterinary pharmaceutical composition and use thereof | |
| KR100329336B1 (ko) | 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형 | |
| KR20020067781A (ko) | 구충용 이버멕틴 주사제 조성물 및 그 제조방법 | |
| EP0427998A2 (en) | A pharmaceutical composition for rectal administration of calcitonin |